New warning OK'd for birth control patch

Jan 21, 2008

The U.S. Food and Drug Administration has approved a warning for the Ortho Evra Contraceptive Transdermal Patch label concerning the risk of blood clots.

The new label will include a warning that users of the birth control patch are at higher risk of pulmonary embolism from blood clots known as venous thromboembolism than women using birth control pills.

"For women that choose to use contraceptives, it is important that they thoroughly discuss with their health care providers the risks and benefits involved," said Dr. Janet Woodcock, the FDA's deputy commissioner for scientific and medical programs. "This is an example of FDA working in tandem with the drug manufacturer to keep the public informed of new safety data and epidemiological studies that may impact health decisions about the use of FDA approved products."

The FDA said it believes Ortho Evra is a safe and effective method of contraception when used according to the labeling, which recommends women with concerns or risk factors for serious blood clots talk with their healthcare provider about using Ortho Evra versus other contraceptive options.

The Ortho Evra Contraceptive Transdermal Patch is manufactured by Johnson and Johnson.

Copyright 2008 by United Press International

Explore further: Britain to offer all infants meningitis B vaccine

Related Stories

Colombia transforms old tires into green housing

7 hours ago

The highlands around the Colombian capital are scattered with small buildings that look like out-of-place igloos but are in fact innovative houses made from the tires that litter the country's roads.

Cassini: Return to Rhea

7 hours ago

After a couple of years in high-inclination orbits that limited its ability to encounter Saturn's moons, NASA's Cassini spacecraft returned to Saturn's equatorial plane in March 2015.

LifePaint spray is Volvo's safety offer for cyclists

7 hours ago

For cyclists sharing the road at dark with cars and pedestrians, a useful motto is to stay safe by staying seen. Volvo, which continues to build on its brand of safety-first, has come out with LifePaint. ...

Recommended for you

Teva buying Auspex for $3.2 billion

16 hours ago

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Oral hepatitis B vaccine could become a reality

18 hours ago

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.